Abstract 2438
Background
This study was carried out as descriptive and cross-sectional in order to determine the compassion fatigue (CF), burnout (BO), compassion satisfaction (CS), perceived stress (PS) and psychological resilience (PR) levels of the nurses working in oncology-hematology and the factors affecting them.
Methods
The sample of the study consisted of 125 oncology-hematology nurses working in two private hospitals, one university hospital. The data were collected by personal information form, professional quality of life scale-IV, PS scale, and PR scale for adults. SPSS 24 package program was used to analyze the data of the study. Descriptive statistics, numbers and percentages and X±SD were used according to the data type. The factors affecting dependent variables were tested with multilevel models (MLM).
Results
In the study, 89.6% (n: 112) of the nurses were women, 80% (n: 100) were unmarried, 70.4% (n: 88) have Bachelor’s degree, mean age was 26.82±5.32, and the average years of total working at oncology was 2.78±2.35, the average weekly working hours was 49.75 ± 4.26, 65.6% (n: 82) said that the social support is not enough. When the mean scores of the nurses were examined, the CF was 13.53±7.25, BO was 20.14±6.77, CS was 37.92±7.40, PS was 32.00±3.44, PR was 135.43±17.29. There was a statistically significant effect of weekly working hour on BO, CS and PS (p < 0.05). 1 hour more work per week leads to a 0.5 point decrease in CS mean scores, 0,45 points increase in BO mean scores and 0,18 points increase in PS mean scores. When we compare the nurses their answers to social support question, nurses who said that social support is insufficient, have 3.1 points higher CF, 2.6 points lower CS, and 8.8 points lower PR mean scores (p < 0.05).
Conclusions
In this study, it was found that nurses had moderate levels of CF, BO and CS. While having social support positively affected the dependent variables, it was found that the increase in the weekly working hours negatively affected. These results are a key finding for the managers of the institutions especially in providing the healthy working life of nurses.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Tuğba Pehlivan.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1285 - Preliminary results of STELLAR-001, a dose escalation phase I study of the anti-C5aR, IPH5401, in combination with durvalumab in advanced solid tumors.
Presenter: Christophe Massard
Session: Poster Display session 3
Resources:
Abstract
3808 - GOLFIG chemo-immunotherapy in metastatic colorectal cancer (mCRC) patients: A fifteen year retrospective analysis
Presenter: Pierpaolo Correale
Session: Poster Display session 3
Resources:
Abstract
5677 - Immune correlates in peripheral blood samples in a preoperative window of opportunity randomized trial of nivolumab with or without tadalafil in resectable squamous cell carcinoma of the head and neck (SCCHN)
Presenter: Larry Harshyne
Session: Poster Display session 3
Resources:
Abstract
4854 - Phase 1 evaluation of AB928, a novel dual adenosine receptor antagonist, combined with chemotherapy or AB122 (anti-PD-1) in patients (pts) with advanced malignancies
Presenter: John Powderly
Session: Poster Display session 3
Resources:
Abstract
4344 - Phase 1 Trial of CV301 in Combination with Anti-PD-1 Therapy in Non-squamous NSCLC
Presenter: Arun Rajan
Session: Poster Display session 3
Resources:
Abstract
4555 - Safety and efficacy results of the combination of DPX-Survivac, pembrolizumab and intermittent low dose cyclophosphamide (CPA) in subjects with advanced and metastatic solid tumors: preliminary results from the hepatocellular carcinoma (HCC), NSCLC, bladder cancer, & MSI-H cohorts
Presenter: Henry Conter
Session: Poster Display session 3
Resources:
Abstract
3012 - Excellent CBR and Prolonged PFS in Non-Squamous NSCLC with Oral CA-170, an Inhibitor of VISTA and PD-L1
Presenter: Vivek Radhakrishnan
Session: Poster Display session 3
Resources:
Abstract
2536 - Phase Ib/II trial of TG4001 (Tipapkinogene sovacivec), a therapeutic HPV-vaccine, and Avelumab in patients with recurrent/metastatic (R/M) HPV-16+ cancers
Presenter: Christophe Le Tourneau
Session: Poster Display session 3
Resources:
Abstract
1845 - Induction of tumor-infiltrating functional CD8 positive cells and PD-L1 expression in esophageal cancer by S-588410
Presenter: Takashi Kojima
Session: Poster Display session 3
Resources:
Abstract
5043 - Comprehensive results of a Phase Ib study with a HER2/neu B-cell peptide vaccine administered with cisplatin and 5-fluorouracil or capecitabine chemotherapy show safety, immunogenicity and clinical response in patients with HER2/Neu overexpressing advanced gastric cancer
Presenter: Ursula Wiedermann
Session: Poster Display session 3
Resources:
Abstract